In December 2025, Johnson & Johnson completed its acquisition of Halda Therapeutics, adding JNJ-6143 and the RIPTAC platform to its oncology portfolio.
PR Newswire news releases · 钛媒体 · 2026-10-25 15:30
View evidence
- CompanyPR Newswire news releases2026-10-25 15:30
In December 2025, Johnson & Johnson completed its acquisition of Halda Therapeutics, adding JNJ-6143 and the RIPTAC platform to its oncology portfolio.
View source - Media钛媒体2026-10-15 10:35View source